A slower ramp-up of Kisunla dosing lowers the rate of dangerous brain swelling, a risk that has made doctors reluctant to ...

Eli Lilly’s Kisunla is now FDA approved for treating patients in the early stages of Alzheimer’s disease. In addition to slowing cognitive decline and disease progression, clinical trial ...

Like Leqembi —an FDA-approved drug for Alzheimer’s made by Eisai and Biogen—Lilly’s Kisunla may slow the progression of Alzheimer’s symptoms. Aduhelm, also made by Biogen, was approved in 2021 but ...

Aduhelm is used to treat Alzheimer's disease. Find out what the recommended dosages are, how to use the drug, and more.

Aduhelm is used to treat early stages of Alzheimer's disease. Find out what the recommended dosages are, how the drug is given, and more.

Biogen is pulling the plug on the controversial drug Aduhelm, the first drug cleared by government health officials for treating Alzheimer's in nearly two decades.

Biogen has returned its Aduhelm rights to Neurimmune, the company that initially developed the antibody Alzheimer’s disease drug. But Biogen isn’t abandoning Alzheimer’s, and its pipeline ...

Biogen will give up ownership and halt sales of Aduhuelm, an Alzheimer's disease drug that met skepticism and scrutiny following its 2021 approval.

Biogen will halt all development and commercialization of Aduhelm following various controversies and setbacks over the past three years.

Stat reports that Billy Dunn, who presided over the controversial approval of the Alzheimer's drug Aduhelm, will retire to pursue other opportunities. Meanwhile, CBS News says the FDA has recently ...

FDA grants accelerated approval to Alzheimer's drug for people with early stage disease About 1 in 9 people ages 65 and older have Alzheimer's.

A report by two House committees found that the Food and Drug Administration's controversial approval of the Alzheimer's drug Aduhelm was "rife with irregularities." ...